Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix ABACIXF +27.01%39 3-Year EPS without NRI Growth Rate is 49.50% as of Mar. 2026, which is 79% above its 10-year median of 27.60. GuruFocus rates ACIXF with a GF Score™ of 39/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 659 Medical Devices & Instruments companies, Acarix AB ranks better than 88.32% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 49.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 38.70% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 26.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Acarix AB was 49.50% per year. The lowest was -33.50% per year. And the median was 27.60% per year.
Acarix AB (OTCPK:ACIXF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Acarix AB 3-Year EPS without NRI Growth Rate Related Terms
ACIXF vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Acarix AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Acarix AB's 3-Year EPS without NRI Growth Rate falls into.
Acarix AB 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 49.50% mean?
Acarix AB (ACIXF) has a 3-Year EPS without NRI Growth Rate of 49.50% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Acarix AB and its competitors. This is 79% above median its historical median of 27.60. According to the industry distribution chart, Acarix AB ranks #77 out of 659 companies in the Medical Devices & Instruments industry, placing it in the top 11.7%.
Is Acarix AB's 3-Year EPS without NRI Growth Rate too high?
Acarix AB's current 3-Year EPS without NRI Growth Rate of 49.50% is 79% above median its 10-year median of 27.60. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.10. Acarix AB's value of 49.50% is 511.1% above this industry median. Based on the distribution chart, Acarix AB ranks #77 out of 659 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #77 out of 659 companies for 3-Year EPS without NRI Growth Rate. This places Acarix AB in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.10. Acarix AB's value of 49.50% is 511.1% above this benchmark. While the company's 10-year median is 27.60 vs. the industry median of 8.10, Acarix AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.10, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current 3-Year EPS without NRI Growth Rate of 49.50% is 511.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current 3-Year EPS without NRI Growth Rate is 49.50%, which is 79% above median its own 10-year median of 27.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 38.5% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 49.50%, which is 79% above median its 10-year median of 27.60 and 511.1% above the Medical Devices & Instruments industry median of 8.10. Acarix AB's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Acarix AB (ACIXF), the current 3-Year EPS without NRI Growth Rate is 49.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 38.5% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Significantly Overvalued.
Key valuation signals for ACIXF:
3-Year EPS without NRI Growth Rate: 49.50% (79% above median its 10-year median of 27.60)
GF Value™: $0.02 vs. price of $0.03 (38.5% above fair value)
Industry Position: 511.1% above the Medical Devices & Instruments median (#77 of 659)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
39GF Score
Get the complete analysis for ACIXF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
